Role of Epstein-Barr Virus and Human Papillomavirus Coinfection in Cervical Cancer: Epidemiology, Mechanisms and Perspectives.
Epstein-Barr virus
cervical cancer
coinfection
human papillomavirus
tissue-infiltrating lymphocytes
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
21 Aug 2020
21 Aug 2020
Historique:
received:
17
07
2020
revised:
16
08
2020
accepted:
18
08
2020
entrez:
26
8
2020
pubmed:
26
8
2020
medline:
26
8
2020
Statut:
epublish
Résumé
High-risk human papillomavirus (HR-HPV) is etiologically associated with the development and progression of cervical cancer, although other factors are involved. Epstein-Barr virus (EBV) detection in premalignant and malignant tissues from uterine cervix has been widely reported; however, its contribution to cervical cancer development is still unclear. Here, a comprehensive analysis regarding EBV presence and its potential role in cervical cancer, the frequency of EBV/HR-HPV coinfection in uterine cervix and EBV infection in tissue-infiltrating lymphocytes were revised. Overall, reports suggest a potential link of EBV to the development of cervical carcinomas in two possible pathways: (1) Infecting epithelial cells, thus synergizing with HR-HPV (direct pathway), and/or (2) infecting tissue-infiltrating lymphocytes that could generate local immunosuppression (indirect pathway). In situ hybridization (ISH) and/or immunohistochemical methods are mandatory for discriminating the cell type infected by EBV. However, further studies are needed for a better understanding of the EBV/HR-HPV coinfection role in cervical carcinogenesis.
Identifiants
pubmed: 32839399
pii: pathogens9090685
doi: 10.3390/pathogens9090685
pmc: PMC7557835
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Gynecol Oncol. 1993 Aug;50(2):168-72
pubmed: 8397152
Mol Pathol. 1999 Apr;52(2):97-103
pubmed: 10474689
J Med Virol. 2000 Dec;62(4):410-5
pubmed: 11074467
J Natl Cancer Inst. 2003 Sep 3;95(17):1336-43
pubmed: 12953088
J Virol Methods. 2001 Apr;93(1-2):23-32
pubmed: 11311340
Cancer Res. 2007 Mar 1;67(5):1970-8
pubmed: 17332324
Int J Gynecol Cancer. 2008 Jul-Aug;18(4):785-9
pubmed: 17868341
Front Oncol. 2014 Oct 21;4:285
pubmed: 25374842
Cancer Res. 2006 Dec 15;66(24):11668-76
pubmed: 17178861
Pol J Microbiol. 2004;53(2):95-9
pubmed: 15478354
PLoS Pathog. 2015 Mar 19;11(3):e1004656
pubmed: 25790223
J Virol. 2013 Oct;87(19):10515-23
pubmed: 23824821
Int J Cancer. 2002 Oct 10;101(5):427-33
pubmed: 12216070
J Oral Pathol Med. 2015 Jan;44(1):28-36
pubmed: 25040496
Br J Cancer. 2000 Dec;83(11):1565-72
pubmed: 11076670
J Pathol. 2004 Jan;202(1):23-33
pubmed: 14694518
PLoS One. 2011;6(10):e25493
pubmed: 21991313
Br J Cancer. 2006 Feb 27;94(4):599-608
pubmed: 16449999
Chin J Cancer. 2014 Nov;33(11):549-55
pubmed: 25223910
Cancer Res. 1999 Dec 15;59(24):6132-6
pubmed: 10626803
Immunity. 2000 Oct;13(4):497-506
pubmed: 11070168
J Huazhong Univ Sci Technolog Med Sci. 2012 Feb;32(1):97-102
pubmed: 22282253
PLoS One. 2015 Apr 01;10(4):e0123029
pubmed: 25830243
J Virol. 2001 Mar;75(6):2929-37
pubmed: 11222718
Gynecol Oncol. 2018 Feb;148(2):317-328
pubmed: 29021084
Bioorg Med Chem Lett. 2012 Mar 1;22(5):2125-9
pubmed: 22300659
J Virol. 2019 Jan 4;93(2):
pubmed: 30381489
Exp Mol Pathol. 2015 Dec;99(3):702-6
pubmed: 26546836
Nat Struct Mol Biol. 2012 Sep;19(9):938-47
pubmed: 22902366
Braz J Microbiol. 2012 Apr;43(2):744-53
pubmed: 24031886
Chin Med J (Engl). 2001 Jul;114(7):718-22
pubmed: 11780335
Oncogene. 2002 Aug 1;21(33):5088-96
pubmed: 12140759
Cancer Causes Control. 2020 Apr;31(4):365-375
pubmed: 32112173
Exp Mol Med. 2015 Jan 23;47:e131
pubmed: 25613728
Infect Genet Evol. 2018 Jul;61:134-144
pubmed: 29518579
Int J Clin Exp Pathol. 2014 Apr 15;7(5):1920-34
pubmed: 24966902
Acta Biochim Pol. 2009;56(2):337-42
pubmed: 19499088
J Clin Pathol. 1993 Oct;46(10):931-5
pubmed: 8227411
Eur J Gynaecol Oncol. 2015;36(5):546-50
pubmed: 26513880
Diagn Pathol. 2015 Jun 02;10:59
pubmed: 26032781
Neoplasia. 2009 Sep;11(9):964-73
pubmed: 19724690
Semin Oncol. 2015 Apr;42(2):291-303
pubmed: 25843733
Br J Cancer. 2011 Mar 29;104(7):1160-7
pubmed: 21386845
Hum Pathol. 2000 Mar;31(3):318-26
pubmed: 10746674
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6467-E6475
pubmed: 27698133
Cancer Res. 1996 Oct 15;56(20):4620-4
pubmed: 8840974
Front Oncol. 2018 Jul 02;8:250
pubmed: 30035100
J Carcinog. 2006 May 10;5:13
pubmed: 16686948
Br J Obstet Gynaecol. 1993 Feb;100(2):149-53
pubmed: 8476807
Clin Adv Hematol Oncol. 2014 Jun;12(6):358-71
pubmed: 25003566
J Virol. 1999 Sep;73(9):7627-32
pubmed: 10438853
Virology. 2004 Jun 20;324(1):17-27
pubmed: 15183049
Oncol Lett. 2018 May;15(5):7537-7544
pubmed: 29725459
Cell Signal. 2004 Oct;16(10):1153-62
pubmed: 15240010
Virol J. 2013 Nov 19;10:340
pubmed: 24252325
Sex Transm Dis. 2018 Oct;45(10):666-672
pubmed: 29664764
Mol Med Rep. 2016 May;13(5):4151-8
pubmed: 27052804
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
J Microbiol Immunol Infect. 2004 Oct;37(5):282-7
pubmed: 15497009
Gynecol Oncol. 1997 Apr;65(1):121-9
pubmed: 9103401
J Virol. 2010 Sep;84(18):9398-407
pubmed: 20631133
Virology. 2016 Aug;495:52-62
pubmed: 27179345
Virology. 2009 Aug 15;391(1):57-63
pubmed: 19552933
Pathol Int. 1997 Aug;47(8):507-11
pubmed: 9293529
FEMS Microbiol Rev. 2019 Nov 1;43(6):674-683
pubmed: 31584659
Rev Med Virol. 2014 May;24(3):142-53
pubmed: 24339346
Gynecol Oncol. 1995 May;57(2):150-7
pubmed: 7537239
Oncoimmunology. 2013 Feb 1;2(2):e23035
pubmed: 23526738
Virchows Arch. 2008 Jun;452(6):621-7
pubmed: 18437417
Arch Virol. 2006 Dec;151(12):2321-35
pubmed: 16862386
Papillomavirus Res. 2017 Dec;4:22-25
pubmed: 29179865
J Virol. 2012 Dec;86(24):13174-86
pubmed: 23015706
Int J Gynecol Cancer. 2005 Mar-Apr;15(2):312-8
pubmed: 15823118
PLoS One. 2017 Jan 5;12(1):e0169290
pubmed: 28056059
PLoS Pathog. 2012;8(5):e1002704
pubmed: 22615564
Cancer. 2014 Feb 1;120(3):363-72
pubmed: 24190575
J Virol. 2012 Jun;86(11):6146-58
pubmed: 22491455
Front Microbiol. 2018 Dec 17;9:3022
pubmed: 30619121
Front Oncol. 2019 Mar 15;9:127
pubmed: 30931253
BMC Infect Dis. 2013 Aug 13;13:373
pubmed: 23941096
Maedica (Bucur). 2016 Mar;11(1):48-54
pubmed: 28465751
Arch Pathol Lab Med. 1999 Nov;123(11):1098-100
pubmed: 10539915
J Virol. 2003 Sep;77(18):9852-61
pubmed: 12941894
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8211-6
pubmed: 12821782
Biochim Biophys Acta. 2011 Nov-Dec;1809(11-12):631-40
pubmed: 21640213
J Virol. 2017 Oct 13;91(21):
pubmed: 28835489
J Virol. 2004 Jun;78(11):5934-45
pubmed: 15140991
Cancer Res. 2001 Aug 1;61(15):5703-6
pubmed: 11479201
Future Virol. 2011 Jan 1;6(1):45-57
pubmed: 21318095
Oncotarget. 2017 Oct 25;8(56):96323-96339
pubmed: 29221209
J Med Virol. 2005 May;76(1):82-8
pubmed: 15778977
Clin Microbiol Infect. 2010 Mar;16(3):262-6
pubmed: 19438642
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
PLoS One. 2012;7(5):e38178
pubmed: 22662279
Methods Mol Biol. 2017;1532:65-78
pubmed: 27873267
Cancer. 1993 Sep 15;72(6):1946-8
pubmed: 8395968
J Virol. 2004 Nov;78(21):11451-60
pubmed: 15479788
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16544-9
pubmed: 25313069
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
J Clin Virol. 2015 Dec;73:70-76
pubmed: 26551071
Oncogene. 2006 Sep 28;25(44):5953-9
pubmed: 16636661
Int J Gynecol Cancer. 2019 Oct;29(8):1317-1326
pubmed: 31455660
Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5
pubmed: 8090780
Hum Vaccin Immunother. 2016 Jul 2;12(7):1936-9
pubmed: 27082145
Sci Rep. 2017 Dec 19;7(1):17810
pubmed: 29259270
J Gen Virol. 2008 Nov;89(Pt 11):2833-2842
pubmed: 18931081
Science. 2003 Nov 21;302(5649):1396-8
pubmed: 14631040
Annu Rev Pathol. 2019 Jan 24;14:29-53
pubmed: 30125149
Rev Med Virol. 2013 Nov;23(6):367-83
pubmed: 23996634
Cancers (Basel). 2018 Mar 17;10(3):
pubmed: 29562599
Int J Biochem Cell Biol. 2007;39(2):402-12
pubmed: 17070091